Breast cancer, Gastric cancer, Colorectal cancer, Glioma
Conditions
Interventions
64Cu-DOTA labeled antibody probes against HER2 and EGFR
Sponsors
National Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with invasive breast cancer, gastric cancer, colorectal cancer or glioma. 2. Age: >20 years, <75 years 3. ECOG performance status: 0-2 4. Capable of imaging by PET 5. Good main organ function 6. Signed informed consent
Exclusion criteria
Exclusion criteria: 1. Severe drug hypersensitivity 2. Ischemic heart disease, cardiomyopathy, congestive heart failure and uncontrolled arrhythmia 3. Active infectious disease, interstitial pneumonia and pulmonary fibrosis 4. Organ insufficiency (bone marrow, liver and kidney) 5. Active synchronous double cancer 6. Pregnancy and lactating (including possibility and intention) 7. Decision of the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visualization of PET imaging with 64Cu-DOTA labeled antibody probes against HER2 and EGFR. Comparison between PET imaging and expression of HER2 and EGFR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of HER2- and EGFR-PET imaging. Comparison between standardized uptake value on PET imaging and expression of HER2 and EGFR. Comparison between intratumoral uptake of 64Cu-DOTA labeled antibody probes and expression of HER2 and EGFR (in specific cases). | — |
Countries
Japan
Contacts
Public ContactKenji Tamura
National Cancer Center Hospital Breast and Medical Oncology
Outcome results
None listed